Sucampo/Takeda drug Amitiza wins 1st FDA nod in OIC non-cancer pain
This article was originally published in Scrip
Executive Summary
Sucampo Pharmaceuticals and its partner Takeda won the US FDA's blessing on 23 April to market Amitiza (lubiprostone) 24mcg twice daily as the first and only oral medicine to treat opioid-induced constipation (OIC) in adults with chronic non-cancer pain.